AK3280

AK3280 is a next-generation, orally bioavailable small molecule anti-fibrotic drug developed as an optimized derivative of pirfenidone. It is designed to improve pharmacokinetic and pharmacological profiles over pirfenidone with enhanced efficacy and better tolerability—particularly reducing gastrointestinal side effects common to current idiopathic pulmonary fibrosis (IPF) therapies. Mechanistically, AK3280 modulates multiple pathways and biomarkers associated with fibrotic processes, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-β) and lysophosphatidic acid (LPA). It acts by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Preclinical studies have demonstrated broad antifibrotic activity across organs such as lung, liver, heart, and skin. The primary clinical focus is on IPF; phase II trials in China showed significant improvements in lung function with a favorable safety profile compared to existing treatments[1][2][3][4][5][6][7][8][9].